You submit a paper to a prestigious journal about the effects of coffee consumption on mesothelioma risk. The first reviewer lauds your clinical and scientific acumen, but expresses concern that your study does not have adequate statistical power. Statistical power refers to which of the following?

The probability of detecting an association when an association does exist.

The probability of detecting an association when no association exists.

The probability of not detecting an association when an association does exist.

The square root of the variance.

A health system implements a new sepsis protocol across 20 hospitals. A researcher plans to evaluate effectiveness using a stepped-wedge cluster randomized design where hospitals sequentially adopt the protocol every 3 months. She calculates sample size based on individual patient outcomes (mortality) needing 2,000 patients total. The biostatistician identifies a critical error. Evaluate what modification is needed.

Account for intra-cluster correlation coefficient (ICC) requiring substantial sample size inflation

Adjust for multiple time periods using Bonferroni correction

Use hospital-level outcomes instead of patient-level outcomes as unit of analysis

Increase alpha to 0.10 to account for cluster randomization reducing power

Include random effects for both hospital and time period in power calculation

A 41-year-old research fellow designs a non-inferiority trial comparing oral to IV antibiotics for osteomyelitis. She sets the non-inferiority margin at 10% (cure rate difference), expects 85% cure in both groups, and calculates 300 patients per arm for 80% power with α=0.025 (one-sided). Her mentor suggests this underestimates required sample size. Evaluate the mentor's concern.

Correct; non-inferiority trials require larger samples than superiority trials for equivalent power

Incorrect; non-inferiority trials actually require smaller samples due to less stringent hypotheses

Correct; dropout rates in antibiotic trials necessitate 20% inflation of calculated sample size

Incorrect; the calculation appropriately uses one-sided alpha for non-inferiority testing

Correct; the margin should be set at 5% requiring doubling of sample size

A pharmaceutical company tests a new antidepressant in 500 patients (250 per arm) and finds a 2-point improvement on a 52-point depression scale compared to placebo (p=0.04). The study was originally powered to detect a 4-point difference. The company seeks FDA approval citing statistical significance. Analyze the regulatory and scientific implications.

Approval not warranted; observed effect is smaller than pre-specified clinically meaningful difference

Approval warranted; the study achieved statistical significance with adequate power

Approval warranted; post-hoc power analysis shows adequate power for 2-point difference

Approval not warranted; the study was underpowered for the observed effect size

Approval warranted if sensitivity analyses confirm robustness of findings

A meta-analysis of 5 previous trials testing a surgical technique shows a pooled effect size of 15% complication reduction (from 20% to 17%, p=0.30, I²=0%). An investigator wants to design a definitive trial. She calculates that 1,200 patients per arm would provide 80% power to detect this 3% absolute difference. Analyze whether this sample size is justified.

Not justified; a 3% absolute reduction lacks clinical significance for most surgical outcomes

Not justified; the high I² indicates substantial heterogeneity making pooled estimates unreliable

Justified; the non-significant p-value indicates need for larger, definitive trial

Justified only if cost-effectiveness analysis supports the intervention

Justified; the meta-analysis provides the best estimate of true effect size

Group sequential designs for USMLE Step 1: High-Yield Biostatistics Lessons

Group Sequential Designs - Peeking Without Penalty

Definition: A clinical trial design allowing periodic data analysis at pre-specified points.
Purpose: To stop a trial early for efficacy, futility, or harm, thus saving resources and protecting subjects.
Challenge: Multiple analyses ("peeking") inflate the overall Type I error rate ($α$).
Solution: Use pre-planned statistical stopping boundaries to adjust the significance level at each interim look.
- O'Brien-Fleming: Conservative early on; requires very strong evidence to stop the trial.
- Pocock: Uses the same significance boundary for all interim analyses.

⭐ The O'Brien-Fleming method is widely used as it preserves overall statistical power and makes it difficult to stop a trial early without a very large treatment effect, reducing the risk of a premature decision.

Group Sequential Plot with Efficacy and Futility Boundaries

Alpha-Spending Functions - Slicing the Error Pie

Core Idea: A pre-defined plan for how to "spend" the total Type I error probability ($\alpha$, usually 0.05) across multiple interim analyses in a group sequential trial.
Mechanism: At each "peek" at the data, a portion of the total $\alpha$ is used up. This prevents inflating the overall Type I error rate from repeated testing.

Boundaries for different group sequential designs

Common Approaches:
- O'Brien-Fleming: Spends very little $\alpha$ early on.
  - Conservative early; requires very strong evidence to stop.
  - Preserves statistical power; most commonly used.
- Pocock: Spends $\alpha$ more evenly across looks.
  - Easier to stop early, but loses some power compared to OBF.

⭐ Exam Favorite: The O'Brien-Fleming method is preferred because its final critical value is very close to the conventional 0.05, preserving statistical power and making results more comparable to traditional fixed-sample trials.

Stopping Boundaries - When to Say When

Stopping boundaries are pre-specified statistical thresholds in group sequential trials that allow for early termination for efficacy or futility. These boundaries are defined before the trial begins, based on an "alpha-spending" function.

Efficacy Boundary: If the test statistic crosses this line at an interim analysis, the trial is stopped, and the treatment is declared effective.
Futility Boundary: If the statistic crosses this line, it indicates the treatment is unlikely to prove effective, and the trial is stopped. This saves resources and protects participants.
Common Methods:
- O'Brien-Fleming: Conservative early boundaries. Harder to stop early, but preserves statistical power. Most common.
- Pocock: Constant boundaries at each look. Easier to stop early, but requires a larger maximum sample size.

⭐ The O'Brien-Fleming method is favored because its conservative early boundaries minimize the risk of stopping a trial due to a random high early on, thus preserving the overall study power close to that of a traditional fixed-sample design.

Advantages & Disadvantages - The Good & The Bad

Advantages
- Ethical: Can stop a trial early for clear efficacy or harm, protecting patients from inferior treatments.
- Efficient: Saves time and resources if a strong conclusion is reached before the planned end.
Disadvantages
- Complex: Requires special statistical methods to avoid inflating Type I error from multiple analyses.
- Logistical Burden: Needs an independent Data & Safety Monitoring Board (DSMB).

⭐ Multiple analyses increase the chance of a false positive (Type I error). Interim analyses must therefore use much stricter p-value boundaries (e.g., p < 0.005) to maintain an overall trial alpha of 0.05.

High‑Yield Points - ⚡ Biggest Takeaways

Group sequential designs allow for interim analyses of data at predetermined points during a clinical trial.

The primary goal is to stop the trial early for overwhelming efficacy or futility, enhancing ethical standards.

Multiple analyses inflate the overall Type I error rate (α), increasing the chance of a false-positive result.

Alpha-spending functions are used to adjust significance boundaries at each look, preserving the overall α.

This approach can significantly reduce trial duration and cost.

All stopping rules and analysis plans must be pre-specified in the study protocol.

Continue reading on Oncourse

CONTINUE READING — FREE

or get the app

App Store|Google Play